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frequently deleted in both smokers group. Two genes in the ampliﬁed 
region involved in the regulation of transcription (ZNF43 and ZNF675) 
are down-regulated in squamous cell carcinomas in smokers. Addition-
ally, ZNF43 is up- regulated in cell lines exposed to sodium arsenite.
Conclusions: Using high resolution tiling path array CGH, we have 
detected different patterns for copy number alterations in squamous cell 
lung carcinomas from patients with chronic exposure to arsenic. Simi-
larity of alterations in some regions for NS-As and S-noAs suggests 
existence of common pathways used for both carcinogens in SqCC 
development. Further analysis of genes and pathways affected could 
give some clues about signiﬁcant mechanisms involved.
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Introduction: Neuropilin-1 (NP1), originally identiﬁed as a receptor 
for the semaphorin/collapsin family of neuronal mediators, has recently 
been documented as an isoform-speciﬁc receptor for VEGF165 on a 
number of tumour cell types. At present, it is unclear as to the mecha-
nism of NP1 signalling in lung tumour cells. We investigated the role of 
the phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein 
kinase (MAPK) cell signalling pathways in hypoxic lung tumour cells 
and the effect of blocking the NP1 receptor on these survival pathways.
Methods: We have previously shown that NP1 and vascular endo-
thelial growth factor (VEGF) are expressed in the non-small cell lung 
cancer cells, H647, A549 and SKMES1, at the mRNA and protein 
levels by RT-PCR and Western blotting, respectively. Phosphorylated 
levels of the downstream cell signalling proteins of the PI3K (phospha-
tidylinositol 3-kinase) and MAPK (mitogen-activated protein kinase) 
pathways, Akt and Erk1/2, respectively, were examined in lung tumour 
tissues relative to their matched normal tissue. A549 (adenocarcinoma) 
and SKMES1 (squamous cell carcinoma) cells were treated with a 
neutralising antibody to NP1 (1µg/ml) under hypoxia (0.1% O2), in the 
presence or absence of recombinant human VEGF (100ng/ml). Expres-
sion levels of phospho-Akt and phospho-Erk1/2 were examined by 
Western blot. Expression levels and localisation of both phosphorylated 
proteins in response to NP1 blockade under hypoxia, were examined 
in A549 and SKMES1 cells using the Cellomics™ IN Cell Analyzer 
1000. Apoptosis was assessed by Flow Cytometry using AnnexinV/
Propidium Iodide staining. 
Results: In a panel of adenocarcinoma and squamous cell lung carci-
nomas from a series of lung cancer patients, pAkt and pErk1/2 levels 
were overexpressed relative to their matched normal tissues. In A549 
and SKMES1 cell lines, hypoxia increased phospho-Akt relative to 
cells grown under normoxia. Inclusion of NP1 antibodies abrogated 
this hypoxia-induced increase in phospho-Akt in both cell lines, while 
a downregulation of phospho-Erk was seen in SKMES1 cells only. NP1 
blockade under hypoxia signiﬁcantly induced apoptosis in both cell 
lines relative to cells grown under normoxia and hypoxia alone. 
Conclusion: These results suggest a role for the PI3K and MAPK 
signalling pathways in the survival of lung tumour cells under hypoxia, 
an effect that can be inhibited by blocking NP1.
As NP1 lacks a cytoplasmic tyrosine kinase signalling domain, the 
mechanism of NP1 signalling via the classical VEGF receptors, Flt-
(VEGFR1), KDR(VEGFR2), or alternatively, via the Plexin family of 
receptors, is currently under investigation.
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Background: Cigarette smoke is the major cause of lung cancer, 
the leading cause of cancer deaths, and COPD (Chronic Obstructive 
Pulmonary Disease), the fourth leading cause of death in the United 
States. There is now a large body of evidence to indicate that smok-
ers with COPD have increased risk of developing lung cancer. Studies 
have shown that the incidence of lung cancer in smokers with COPD 
is about 4 times higher than in smokers without COPD that have been 
matched for age, sex, occupation, and smoking history. The chronic 
airway inﬂammation associated with COPD may create a pulmonary 
micro-environment that promotes cellular proliferation and carcino-
genesis. In order to identify genes which are speciﬁcally deregulated 
in lung cancer, one needs to consider COPD as one of the confounding 
factors to create normal expression baseline. Furthermore, the dis-
covery of genes differentially altered between lung patients with and 
without COPD may clarify the pathogenic mechanisms that increase 
lung cancer risk from chronic airway inﬂammation. 
Methods: Gene expression proﬁles of 50 lung tumors and matched 
normal lung tissues from 29 subjects with COPD and 21 subjects 
without COPD were analyzed using Agilent platform. Using multiple 
permutation-based approaches, differentially regulated genes between 
the subgroups were identiﬁed. Genes which have p-values less than 10-6 
were selected for further analysis.
Results: Multiple permutation-based approaches identiﬁed 450 genes 
that are different in the tumors in patients with COPD versus those 
without COPD. Similar approaches identiﬁed 381 genes in non-neo-
plastic lung tissues of patients with and without COPD. The genes in 
the tumor tissue analysis include tumor suppressor and oncogenes; 
and those in the non-neoplastic tissue analysis include genes that are 
involved in growth and differentiation of epithelial cells and connective 
tissue formation.
Conclusions: The number of genes deregulated in COPD is statisti-
cally signiﬁcant, which suggests that COPD status has to be considered 
as an important co-variable when conducting genomic analysis in lung 
cancer and in making comparison between tumor and normal tissue. 
Further analysis on the genes identiﬁed between lung patients with and 
without COPD may clarify the relationship between these two condi-
tions, which are etiologically linked and often comorbid. 
